OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc.(OKUR)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
SELL
SELL for 1 day
PROFIT SINCE LAST BUY
-21.73% ▼
LAST CLOSE
$2.63
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for OKUR

11/13/2026: OKUR (1-star) is a SELL. SELL for 1 day. Simulated Profits (-21.73%). Updated daily EoD!

OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision small-molecule medicines for oncology. Its primary strength lies in a structure-based drug design platform that aims to selectively inhibit PI3Kα mutations. The investment story centers on the potential of its next-generation pipeline to deliver durable therapies in underserved cancer and vascular anomaly markets. Key risks include the binary nature of clinical trials, intense competition from well-capitalized pharmaceutical firms, and the absence of current revenue. The stock is best suited for growth-oriented investors with high risk tolerance who are closely monitoring upcoming IND submissions and clinical data milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers potential for significant upside if its clinical candidates succeed but comes with extreme binary risk.
Momentum investorWeak fitMomentum is generally low for early-stage biotech without near-term commercial catalysts, though interest may increase during trial data readouts.
Value investorWeak fitAs a loss-making clinical-stage company, traditional value metrics like P/E or dividend yield are not applicable.
Dividend investorWeak fitThe company is in an early-stage investment phase and does not pay dividends.
Low-risk investorWeak fitBiotechnology stocks are inherently volatile and carry high risk of permanent capital loss.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotech stocks are susceptible to massive price swings based on data readouts.
Valuation riskMedium / highValuations are highly speculative as they are based on future clinical probability rather than current earnings.
Competition risk (oncology)HighMany larger competitors are developing similar PI3K inhibitors, potentially crowding out market space.
Business qualityMediumThe company is at a very early stage of maturity with limited commercial validation.
Dividend incomeLow / noneInvestors should expect zero income as capital is prioritized for clinical development.
Execution riskHighThe company must successfully navigate complex clinical trials and FDA processes to reach the market.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 108.33M USD
Price to earnings Ratio -
1Y Target Price 15.25
Price to earnings Ratio -
1Y Target Price 15.25
Volume (30-day avg) 394.9K shares
Beta 0.73
52 Weeks Range 2.01 - 5.38
Updated Date 11/14/2026
52 Weeks Range 2.01 - 5.38
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.98

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -45.73%
Avg. Invested days 18
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
OKUR receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
OKUR has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-13.0%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
OKUR's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
OKUR's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-13.0%, negative) and free-cash-flow growth (-1.4%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 93.6% and approximately 46.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 10.17% supports management-shareholder alignment.

Top 5 Institutional Investors

RA Capital Management, LLC 9.71%
Bvf Inc 7.86%
StepStone Group LLC 6.46%
ADAR1 Capital Management LLC 5.44%
Vivo Capital, LLC 4.68%

Unit Economics (Per $1K Revenue)

★★★★★
OKUR generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
OKUR has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Research and DevelopmentFocuses on developing PI3Kα-targeted small-molecule oncology drugs.The company does not currently generate revenue and is purely a research investment.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -38.95M
Price to Sales(TTM) -
Enterprise Value -38.95M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.03
Shares Outstanding 40.50M
Shares Floating 18.69M
Shares Outstanding 40.50M
Shares Floating 18.69M
Percent Insiders 10.17
Percent Institutions 93.57

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.